Invasive Bladder Pressure Tests for Refractory Overactive Bladder May Be Avoided

Follow Drugslib on

Medically reviewed by Carmen Pope, BPharm. Last updated on April 1, 2025.

By Elana Gotkine HealthDay Reporter

TUESDAY, April 1, 2025 -- Urodynamics plus comprehensive clinical assessment (CCA) is not superior to CCA only for women with refractory overactive bladder or urgency predominant mixed urinary incontinence, according to a study published in the March 29 issue of The Lancet to coincide with the 40th Annual European Association of Urology Congress, held from March 21 to 24 in Madrid.

Mohamed Abdel-Fattah, M.D., from the University of Aberdeen in the United Kingdom, and colleagues conducted a superiority trial in 63 U.K. hospitals to compare the clinical effectiveness and cost-effectiveness of urodynamics plus CCA versus CCA only in the management of women with refractory overactive bladder symptoms. Women aged 18 years or older with refractory overactive bladder or urgency predominant mixed urinary incontinence, with failed conservative management and being considered for invasive treatment, were randomly assigned to urodynamics plus CCA versus CCA only (550 and 549 patients, respectively).

The researchers found that the participant-reported success rates of "very much improved" or "much improved" were not superior in the urodynamics plus CCA group versus the CCA-only group at the final follow-up time point at 15 months after randomization. Low and similar serious adverse events were seen between the groups. Per quality-adjusted life year (QALY) gained, the incremental cost-effectiveness ratio was £42,643. At a willingness-to-pay threshold of £20,000 per QALY gained, the cost-effectiveness acceptability curve showed urodynamics had a 34 percent probability of being cost-effective, which reduced further when extrapolated over the patient's lifetime.

"Significantly more women who underwent CCA only report earlier improvement in their symptoms," the authors write.

Several authors disclosed ties to the biopharmaceutical industry.

Abstract/Full Text

Editorial (subscription or payment may be required)

More Information

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2025-04-02 06:00

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords